Overview

A Phase II Combination of Trastuzumab and Ixabepilone Versus Trastuzumab and Docetaxel in Patients With Advanced and/or Metastatic Breast Cancer

Status:
Completed

Trial end date:
2011-11-01

Target enrollment:

Participant gender:

Summary

The purpose of this randomized, Phase 2 open-label study was to assess the response rate of participants with Human Epidermal Growth Factor Receptor 2 (Her2+) locally advanced and/or metastatic breast cancer (not previously treated with chemotherapy or trastuzumab) to treatment with ixabepilone plus trastuzumab and/or docetaxel plus trastuzumab.

Phase:

Phase 2

Details

Lead Sponsor:

R-Pharm

Treatments:

Docetaxel
Epothilones
Trastuzumab